- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Larimar Therapeutics Inc (LRMR)
Track the Larimar Therapeutics Inc share price today and view real-time LRMR share price data, including charts, technicals, and key financials. View the LRMR premarket stock price ahead of the market session or assess the after hours quote. Explore LRMR stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Larimar Therapeutics Inc Stock Price Today?
The Larimar Therapeutics Inc stock price today is 4.100.
What Is the Stock Symbol for Larimar Therapeutics Inc?
The stock symbol for Larimar Therapeutics Inc is ""LRMR.""
What Stock Exchange Does Larimar Therapeutics Inc Trade On?
Larimar Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Larimar Therapeutics Inc a Good Stock to Buy?
Determining whether Larimar Therapeutics Inc or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LRMR quote. (ISIN: US5171251003)
What Is the Larimar Therapeutics Inc Stock Price Today?
The Larimar Therapeutics Inc stock price today is 4.100.
What Is the Stock Symbol for Larimar Therapeutics Inc?
The stock symbol for Larimar Therapeutics Inc is ""LRMR.""
What Stock Exchange Does Larimar Therapeutics Inc Trade On?
Larimar Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Larimar Therapeutics Inc a Good Stock to Buy?
Determining whether Larimar Therapeutics Inc or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LRMR quote. (ISIN: US5171251003)
4.100
-0.060(-1.44%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.020
4.160
52 wk Range
2.715
6.420
LRMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.0204.160
52 wk Range
2.7156.420
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LRMR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
14.300
Upside
+248.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Form 4 Larimar Therapeutics Inc For: 8 July- Investing.com
- Form 4 Larimar Therapeutics Inc For: 8 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 14.300
(+248.78% Upside)
Larimar Therapeutics Inc SWOT Analysis
Nomlabofusp Promise | Larimar's lead drug candidate shows potential to address the root cause of Friedreich's ataxia, positioning the company at the forefront of FA treatment research |
Clinical Milestones | Explore Larimar's progress in adult and pediatric trials, with key data releases expected to serve as potential catalysts for stock performance |
Regulatory Landscape | Learn about Larimar's strategy for accelerated approval and how potential FDA easements for rare diseases could impact the company's timeline |
Market Dynamics | Delve into Larimar's positioning in the evolving FA treatment market, with analyst price targets ranging from $10 to $40 despite recent stock volatility |
Earnings
Latest Release
04/08/2026
EPS / Forecast
-0.30 / -0.38
Revenue / Forecast
-- / --
Compare LRMR to Peers and Sector
Metrics to compare | LRMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLRMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −5.2x | −0.4x | |
PEG Ratio | 0.11 | −0.12 | 0.00 | |
Price/Book | 3.3x | 4.0x | 2.6x | |
Price / LTM Sales | - | 410.3x | 3.0x | |
Upside (Analyst Target) | 202.3% | 99.5% | 46.9% | |
Fair Value Upside | Unlock | −9.8% | 5.3% | Unlock |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Larimar Therapeutics Inc (LRMR) Stock Price Today?
The Larimar Therapeutics Inc stock price today is 4.100 USD.
What Stock Exchange Does Larimar Therapeutics Inc Trade On?
Larimar Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Larimar Therapeutics Inc?
The stock symbol for Larimar Therapeutics Inc is "LRMR."
What Is the Larimar Therapeutics Inc Market Cap?
As of today, Larimar Therapeutics Inc market cap is 429.010M USD.
What Is Larimar Therapeutics Inc's Earnings Per Share (TTM)?
The Larimar Therapeutics Inc EPS (TTM) is -1.926.
When Is the Next Larimar Therapeutics Inc Earnings Date?
Larimar Therapeutics Inc will release its next earnings report on 05/11/2026.
From a Technical Analysis Perspective, Is LRMR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Larimar Therapeutics Inc Stock Split?
Larimar Therapeutics Inc has split 1 times.
How Many Employees Does Larimar Therapeutics Inc Have?
Larimar Therapeutics Inc has 71 employees.
What is the current trading status of Larimar Therapeutics Inc (LRMR)?
As of 26/08/2026, Larimar Therapeutics Inc (LRMR) is trading at a price of 4.100 USD, with a previous close of 4.160 USD. The stock has fluctuated within a day range of 4.020 USD to 4.160 USD, while its 52-week range spans from 2.715 USD to 6.420 USD.
What Is Larimar Therapeutics Inc (LRMR) Price Target According to Analysts?
The average 12-month price target for Larimar Therapeutics Inc is 14.300 USD, with a high estimate of 26 USD and a low estimate of 5 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +248.78% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.